OBJECTIVE: The optimal management of mitral regurgitation (MR) in patients with cardiomyopathy has been controversial. Minimally invasive fibrillating mitral valve replacement (mini-MVR) might limit postoperative morbidity and mortality by minimizing recurrent MR. We hypothesized that mini-MVR with complete chordal sparing would offer low mortality and halt left ventricular (LV) remodeling in patients with severe cardiomyopathy and severe MR. METHODS: From January 2006 to August 2009, 65 patients with an LV ejection fraction (LVEF) of ≤35% underwent mini-MVR. The demographic, echocardiographic, and clinical outcomes were analyzed. RESULTS: The operative mortality compared with the Society of Thoracic Surgeons-predicted mortality was 6.2% versus 6.6%. It was 5.6% versus 7.4% for patients with an LVEF of ≤20% and 8.3% versus 17.9% among patients with a Society of Thoracic Surgeons-predicted mortality of ≥10%. At a median follow-up of 17 months, no recurrent MR or change in the LV dimensions or LVEF had developed, but the right ventricular systolic pressure had decreased (P=.02). At the first postoperative visit and latest follow-up visit, the New York Heart Association class had decreased from 3.0±0.6 to 1.7±0.7 and 2.0±1.0, respectively (P<.0001 for both). Patients with an LVEF of ≤20% and LV end-diastolic diameter of ≥6.5 cm were more likely to meet a composite of death, transplantation, or LV assist device insertion (P=.046). CONCLUSIONS: Our results have shown that mini-MVR is safe in patients with advanced cardiomyopathy and resulted in no recurrent MR, stabilization of the LVEF and LV dimensions, and a decrease in right ventricular systolic pressure. This mini-MVR technique can be used to address severe MR in patients with advanced cardiomyopathy.
OBJECTIVE: The optimal management of mitral regurgitation (MR) in patients with cardiomyopathy has been controversial. Minimally invasive fibrillating mitral valve replacement (mini-MVR) might limit postoperative morbidity and mortality by minimizing recurrent MR. We hypothesized that mini-MVR with complete chordal sparing would offer low mortality and halt left ventricular (LV) remodeling in patients with severe cardiomyopathy and severe MR. METHODS: From January 2006 to August 2009, 65 patients with an LV ejection fraction (LVEF) of ≤35% underwent mini-MVR. The demographic, echocardiographic, and clinical outcomes were analyzed. RESULTS: The operative mortality compared with the Society of Thoracic Surgeons-predicted mortality was 6.2% versus 6.6%. It was 5.6% versus 7.4% for patients with an LVEF of ≤20% and 8.3% versus 17.9% among patients with a Society of Thoracic Surgeons-predicted mortality of ≥10%. At a median follow-up of 17 months, no recurrent MR or change in the LV dimensions or LVEF had developed, but the right ventricular systolic pressure had decreased (P=.02). At the first postoperative visit and latest follow-up visit, the New York Heart Association class had decreased from 3.0±0.6 to 1.7±0.7 and 2.0±1.0, respectively (P<.0001 for both). Patients with an LVEF of ≤20% and LV end-diastolic diameter of ≥6.5 cm were more likely to meet a composite of death, transplantation, or LV assist device insertion (P=.046). CONCLUSIONS: Our results have shown that mini-MVR is safe in patients with advanced cardiomyopathy and resulted in no recurrent MR, stabilization of the LVEF and LV dimensions, and a decrease in right ventricular systolic pressure. This mini-MVR technique can be used to address severe MR in patients with advanced cardiomyopathy.
Authors: Michael A Acker; Steven Bolling; Richard Shemin; James Kirklin; Jae K Oh; Douglas L Mann; Mariell Jessup; Hani N Sabbah; Randall C Starling; Spencer H Kubo Journal: J Thorac Cardiovasc Surg Date: 2006-07-31 Impact factor: 5.209
Authors: G Schuler; K L Peterson; A Johnson; G Francis; G Dennish; J Utley; P O Daily; W Ashburn; J Ross Journal: Circulation Date: 1979-06 Impact factor: 29.690
Authors: Audrey H Wu; Keith D Aaronson; Steven F Bolling; Francis D Pagani; Kathy Welch; Todd M Koelling Journal: J Am Coll Cardiol Date: 2005-02-01 Impact factor: 24.094
Authors: Edwin C McGee; A Marc Gillinov; Eugene H Blackstone; Jeevanantham Rajeswaran; Gideon Cohen; Farzad Najam; Takahiro Shiota; Joseph F Sabik; Bruce W Lytle; Patrick M McCarthy; Delos M Cosgrove Journal: J Thorac Cardiovasc Surg Date: 2004-12 Impact factor: 5.209
Authors: Traves D Crabtree; Marci S Bailey; Marc R Moon; Nabil Munfakh; Michael K Pasque; Jennifer S Lawton; Nader Moazami; Kristen A Aubuchon; Ashraf S Al-Dadah; Ralph J Damiano Journal: Ann Thorac Surg Date: 2008-05 Impact factor: 4.330
Authors: Daniel T Matthews; Catherine N Le; Ivan M Robbins; Michael R Petracek; Meredith E Pugh; Evan L Brittain; Anna R Hemnes Journal: Pulm Circ Date: 2016-06 Impact factor: 3.017
Authors: Megha H Talati; Evan L Brittain; Joshua P Fessel; Niki Penner; James Atkinson; Mitch Funke; Carrie Grueter; W Gray Jerome; Michael Freeman; John H Newman; James West; Anna R Hemnes Journal: Am J Respir Crit Care Med Date: 2016-09-15 Impact factor: 21.405